Description
While inflammatory processes and diagnostic criteria are well-reviewed, there is a critical absence of validated, accessible blood-based biomarkers for early AD detection in community or primary care contexts. Current papers focus on established diagnostic markers rather than screening tools for preclinical or prodromal stages.